Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Chronic Myeloid Leukemia (CML), Newly Diagnosed Age: Adult |
Dose: Oral – 300 mg Frequency: every 12 hours Note: Indicated for initial treatment of newly diagnosed Philadelphia chromosome positive chronic phase chronic myeloid leukemia (Ph+ CP-CML) |
|
Indication: Chronic Myeloid Leukemia (CML), Resistant/Intolerant Age: Adult |
Dose: Oral – 400 mg Frequency: every 12 hours Note: Indicated for treatment of chronic phase and accelerated phase Ph+ CML in patients resistant to or intolerant to prior therapy that included imatinib |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: less than 18 years old |
Dose: Not recommended Note: Not recommended |
Administration
- Take on empty stomach
- Avoid food for 2 hours before and 1 hour after
Side Effect
- Rash (33%)
- Headache (31%)
- Nausea (31%)
- Pruritus (29%)
- Fatigue (28%)
- Pyrexia (24%)
- Diarrhea (22%)
- Constipation (21%)
- Vomiting (21%)
- Arthralgia (18%)
- Cough (17%)
- Extremity pain (16%)
- Asthenia (14%)
- Muscle spasms (14%)
- Myalgia (14%)
- Abdominal pain (13%)
- Bone pain (13%)
- Back pain (12%)
- Dyspnea (11%)
- Nasopharyngitis (11%)
- Peripheral edema (11%)
- Dizziness
- Insomnia
- Paresthesia
- QT interval prolongation
- HTN
- Palpitations
- QT interval prolongation
- Hyperglycemia
- Hyperkalemia
- Hypomagnesemia
- Neutropenia
- Pancytopenia
- Peripheral arterial occlusive disease
- Tumor lysis syndrome
- Aortic valve sclerosis
- Abscess
- Amnesia
- Dehydration
- QT prolongation and sudden deaths
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Drugs that inhibit gastric acid secretion (e.g. PPIs (Omeprazole, Esomeprazole, Lansoprazole, Pantoprazole, Rabeprazole))
|
May reduce solubility and bioavailability of nilotinib
|
|
Potent CYP3A4 inhibitors, Antiarrhythmics (Amiodarone, Flecainide, Propafenone, Quinidine, Disopyramide, Procainamide) (e.g. amiodarone, disopyramide, quinidine, sotalol), other QT prolonging drugs (e.g. chloroquine, haloperidol, methadone, moxifloxacin, pimozide)
|
Potentially Fatal: May increase nilotinib serum levels and/or increase the risk of QT prolongation
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Long QT syndrome
|
Risk of heart arrhythmia
|
|
Hypokalemia
|
Cardiac complications risk
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Store below 30° C.
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.